{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T17:34:14Z","timestamp":1778607254638,"version":"3.51.4"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-22463-8","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T12:59:02Z","timestamp":1762347542000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["First real-world evidence from the Emilia-Romagna region suggests tamoxifen protects breast cancer patients from COVID-19"],"prefix":"10.1038","volume":"15","author":[{"given":"Sara","family":"Bravaccini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Nicolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Balzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Azzali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Pasini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Mazzotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Gaimari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"De Lucia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Zurlo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Maltoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Pirini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Cortesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Zanoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Maddalena","family":"Tumedei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oriana","family":"Nanni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Cerchione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorio","family":"Sambri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia Borges","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano","family":"Mazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"22463_CR1","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M. et al. SARS-CoV-2 Cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271\u2013280e8 (2020).","journal-title":"Cell"},{"key":"22463_CR2","doi-asserted-by":"publisher","first-page":"7001","DOI":"10.1073\/pnas.2002589117","volume":"117","author":"S Matsuyama","year":"2020","unstructured":"Matsuyama, S. et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc. Natl. Acad. Sci. 117, 7001\u20137003 (2020).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"22463_CR3","doi-asserted-by":"publisher","first-page":"096368972096874","DOI":"10.1177\/0963689720968749","volume":"29","author":"S Ravaioli","year":"2020","unstructured":"Ravaioli, S. et al. ACE2 and TMPRSS2 potential involvement in genetic susceptibility to SARS-COV-2 in cancer patients. Cell. Transpl. 29, 0963689720968749 (2020).","journal-title":"Cell. Transpl."},{"key":"22463_CR4","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1126\/science.abd2985","volume":"370","author":"L Cantuti-Castelvetri","year":"2020","unstructured":"Cantuti-Castelvetri, L. et al. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science 370, 856\u2013860 (2020).","journal-title":"Science"},{"key":"22463_CR5","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1126\/science.abd3072","volume":"370","author":"JL Daly","year":"2020","unstructured":"Daly, J. L. et al. Neuropilin-1 is a host factor for SARS-CoV-2 infection. Science 370, 861\u2013865 (2020).","journal-title":"Science"},{"key":"22463_CR6","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/s41556-023-01096-x","volume":"25","author":"U Gioia","year":"2023","unstructured":"Gioia, U. et al. SARS-CoV-2 infection induces DNA damage, through CHK1 degradation and impaired 53BP1 recruitment, and cellular senescence. Nat. Cell. Biol. 25, 550\u2013564 (2023).","journal-title":"Nat. Cell. Biol."},{"key":"22463_CR7","doi-asserted-by":"publisher","first-page":"eadd4150","DOI":"10.1126\/sciadv.add4150","volume":"8","author":"O Solis","year":"2022","unstructured":"Solis, O. et al. The SARS-CoV-2 Spike protein binds and modulates Estrogen receptors. Sci. Adv. 8, eadd4150 (2022).","journal-title":"Sci. Adv."},{"key":"22463_CR8","doi-asserted-by":"publisher","first-page":"100055","DOI":"10.1016\/j.esmoop.2021.100055","volume":"6","author":"A Toss","year":"2021","unstructured":"Toss, A. et al. Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era. ESMO Open. 6, 100055 (2021).","journal-title":"ESMO Open."},{"key":"22463_CR9","doi-asserted-by":"publisher","first-page":"169","DOI":"10.5144\/0256-4947.2025.169","volume":"45","author":"E Yarikkaya","year":"2025","unstructured":"Yarikkaya, E. et al. Impact of the COVID-19 pandemic on the diagnosis, tumor characteristics, and survival outcomes of colorectal cancer: a retrospective cohort study. Ann. Saudi Med. 45, 169\u2013176 (2025).","journal-title":"Ann. Saudi Med."},{"key":"22463_CR10","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12885-023-11795-1","volume":"24","author":"S Marty","year":"2024","unstructured":"Marty, S. et al. Impact of the Sars-Cov-2 outbreak on the initial clinical presentation of new solid cancer diagnoses: a systematic review and meta-analysis. BMC Cancer. 24, 143 (2024).","journal-title":"BMC Cancer"},{"key":"22463_CR11","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s12672-025-02205-y","volume":"16","author":"Y Wang","year":"2025","unstructured":"Wang, Y. et al. The impact of the COVID-19 pandemic on the diagnosis, treatment, and prognosis of ovarian cancer in the united states: a retrospective cohort study based on the SEER database. Discov Oncol. 16, 545 (2025).","journal-title":"Discov Oncol."},{"key":"22463_CR12","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.3390\/cancers14123029","volume":"14","author":"L Mangone","year":"2022","unstructured":"Mangone, L. et al. Prompt resumption of screening programme reduced the impact of COVID-19 on new breast cancer diagnoses in Northern Italy. Cancers 14, 3029 (2022).","journal-title":"Cancers"},{"key":"22463_CR13","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1210\/me.2013-1098","volume":"27","author":"L Clinckemalie","year":"2013","unstructured":"Clinckemalie, L. et al. Androgen regulation of the TMPRSS2 gene and the effect of a SNP in an androgen response element. Mol. Endocrinol. 27, 2028\u20132040 (2013).","journal-title":"Mol. Endocrinol."},{"key":"22463_CR14","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.jaad.2020.04.032","volume":"83","author":"CG Wambier","year":"2020","unstructured":"Wambier, C. G. & Goren, A. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is likely to be androgen mediated. J. Am. Acad. Dermatol. 83, 308\u2013309 (2020).","journal-title":"J. Am. Acad. Dermatol."},{"key":"22463_CR15","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1158\/2159-8290.CD-13-1010","volume":"4","author":"JM Lucas","year":"2014","unstructured":"Lucas, J. M. et al. The Androgen-Regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. Cancer Discov. 4, 1310\u20131325 (2014).","journal-title":"Cancer Discov"},{"key":"22463_CR16","doi-asserted-by":"publisher","first-page":"11130","DOI":"10.1038\/s41598-021-90491-1","volume":"11","author":"M Baratchian","year":"2021","unstructured":"Baratchian, M. et al. Androgen regulation of pulmonary AR, TMPRSS2 and ACE2 with implications for sex-discordant COVID-19 outcomes. Sci. Rep. 11, 11130 (2021).","journal-title":"Sci. Rep."},{"key":"22463_CR17","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41392-021-00853-4","volume":"6","author":"S Zu","year":"2021","unstructured":"Zu, S. et al. Tamoxifen and clomiphene inhibit SARS-CoV-2 infection by suppressing viral entry. Signal. Transduct. Target. Ther. 6, 435 (2021).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"22463_CR18","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.annonc.2021.01.069","volume":"32","author":"M Montopoli","year":"2021","unstructured":"Montopoli, M. et al. Clinical outcome of SARS-CoV-2 infection in breast and ovarian cancer patients who underwent antiestrogenic therapy. Ann. Oncol. 32, 676\u2013677 (2021).","journal-title":"Ann. Oncol."},{"key":"22463_CR19","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41418-021-00844-6","volume":"29","author":"M Allegretti","year":"2022","unstructured":"Allegretti, M. et al. Repurposing the Estrogen receptor modulator raloxifene to treat SARS-CoV-2 infection. Cell. Death Differ. 29, 156\u2013166 (2022).","journal-title":"Cell. Death Differ."},{"key":"22463_CR20","doi-asserted-by":"publisher","first-page":"101450","DOI":"10.1016\/j.eclinm.2022.101450","volume":"48","author":"E Nicastri","year":"2022","unstructured":"Nicastri, E. et al. A phase 2 randomized, double-blinded, placebo-controlled, multicenter trial evaluating the efficacy and safety of raloxifene for patients with mild to moderate COVID-19. eClinicalMedicine 48, 101450 (2022).","journal-title":"eClinicalMedicine"},{"key":"22463_CR21","doi-asserted-by":"publisher","first-page":"1003469","DOI":"10.3389\/fphar.2022.1003469","volume":"13","author":"ZP Wang","year":"2022","unstructured":"Wang, Z. P., Hua, M., Jiu, T., Ge, R. L. & Bai, Z. Biofunctional roles of Estrogen in coronavirus disease 2019: beyond a steroid hormone. Front. Pharmacol. 13, 1003469 (2022).","journal-title":"Front. Pharmacol."},{"key":"22463_CR22","doi-asserted-by":"publisher","first-page":"e053032","DOI":"10.1136\/bmjopen-2021-053032","volume":"12","author":"M Sund","year":"2022","unstructured":"Sund, M., Fonseca-Rodr\u00edguez, O., Josefsson, A., Welen, K. & Connolly, A. M. F. Association between pharmaceutical modulation of oestrogen in postmenopausal women in Sweden and death due to COVID-19: a cohort study. BMJ Open. 12, e053032 (2022).","journal-title":"BMJ Open."},{"key":"22463_CR23","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1186\/s12916-020-01851-z","volume":"18","author":"U Seeland","year":"2020","unstructured":"Seeland, U. et al. Evidence for treatment with estradiol for women with SARS-CoV-2 infection. BMC Med. 18, 369 (2020).","journal-title":"BMC Med."},{"key":"22463_CR24","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1080\/07357907.2018.1453933","volume":"36","author":"TA Bogush","year":"2018","unstructured":"Bogush, T. A. et al. Tamoxifen never ceases to amaze: new findings on Non-Estrogen receptor molecular targets and mediated effects. Cancer Investig. 36, 211\u2013220 (2018).","journal-title":"Cancer Investig"},{"key":"22463_CR25","doi-asserted-by":"publisher","first-page":"101541","DOI":"10.1016\/j.tranon.2022.101541","volume":"26","author":"S Bravaccini","year":"2022","unstructured":"Bravaccini, S. et al. Why the complications of COVID-19 patients differ in elderly and young cancer patients. Transl Oncol. 26, 101541 (2022).","journal-title":"Transl Oncol."},{"key":"22463_CR26","doi-asserted-by":"publisher","first-page":"105954","DOI":"10.1016\/j.ijantimicag.2020.105954","volume":"55","author":"C Zhang","year":"2020","unstructured":"Zhang, C., Wu, Z., Li, J. W., Zhao, H. & Wang, G. Q. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist Tocilizumab May be the key to reduce mortality. Int. J. Antimicrob. Agents. 55, 105954 (2020).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"22463_CR27","doi-asserted-by":"crossref","unstructured":"Indonesia, D., Martono, N., Fatmawati, M. & Mulyanti, S. of, F. Risk Factors Associated with the Severity of COVID-19. Malays. J. M\u00e9d. Sci.: MJMS 30, 84\u201392 (2023).","DOI":"10.21315\/mjms2023.30.3.7"},{"key":"22463_CR28","doi-asserted-by":"publisher","unstructured":"Ngcobo, N.N. Influence of Ageing on the Pharmacodynamics and Pharmacokinetics of Chronically Administered Medicines in Geriatric Patients: A Review. Clin. Pharmacokinet. 64, 335\u2013367. https:\/\/doi.org\/10.1007\/s40262-024-01466-0 (2025).","DOI":"10.1007\/s40262-024-01466-0"},{"key":"22463_CR29","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s10549-021-06168-w","volume":"187","author":"M Faltinov\u00e1","year":"2021","unstructured":"Faltinov\u00e1, M. et al. Monitoring serum estradiol levels in breast cancer patients during extended adjuvant letrozole treatment after five years of tamoxifen: a prospective trial. Breast Cancer Res. Treat. 187, 769\u2013775 (2021).","journal-title":"Breast Cancer Res. Treat."},{"key":"22463_CR30","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/bs.apcsb.2019.01.001","volume":"116","author":"N Fuentes","year":"2019","unstructured":"Fuentes, N. & Silveyra, P. Chapter three Estrogen receptor signaling mechanisms. Adv. Protein Chem. Struct. Biol. 116, 135\u2013170 (2019).","journal-title":"Adv. Protein Chem. Struct. Biol."},{"key":"22463_CR31","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1210\/me.2014-1315","volume":"29","author":"MA Bennesch","year":"2015","unstructured":"Bennesch, M. A., Picard, D. & Minireview Tipping the balance: Ligand-Independent activation of steroid receptors. Mol. Endocrinol. 29, 349\u2013363 (2015).","journal-title":"Mol. Endocrinol."},{"key":"22463_CR32","doi-asserted-by":"publisher","first-page":"8531","DOI":"10.1074\/jbc.M109592200","volume":"277","author":"DM Klotz","year":"2002","unstructured":"Klotz, D. M. et al. Requirement of Estrogen receptor-\u03b1 in Insulin-like growth Factor-1 (IGF-1)-induced uterine responses and in vivo evidence for IGF-1\/Estrogen receptor Cross-talk*. J. Biol. Chem. 277, 8531\u20138537 (2002).","journal-title":"J. Biol. Chem."},{"key":"22463_CR33","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1159\/000354253","volume":"8","author":"M Giuliano","year":"2013","unstructured":"Giuliano, M., Trivedi, M. V. & Schiff, R. Bidirectional crosstalk between the Estrogen receptor and human epidermal growth factor receptor 2 signaling pathways in breast cancer: molecular basis and clinical implications. Breast Care. 8, 256\u2013262 (2013).","journal-title":"Breast Care"},{"key":"22463_CR34","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1152\/physrev.2001.81.4.1535","volume":"81","author":"S Nilsson","year":"2001","unstructured":"Nilsson, S. et al. Mechanisms of Estrogen action. Physiol. Rev. 81, 1535\u20131565 (2001).","journal-title":"Physiol. Rev."},{"key":"22463_CR35","first-page":"2435","volume":"10","author":"RJ Pietras","year":"1995","unstructured":"Pietras, R. J. et al. HER-2 tyrosine kinase pathway targets Estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10, 2435\u20132446 (1995).","journal-title":"Oncogene"},{"key":"22463_CR36","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.2337\/dc10-0770","volume":"33","author":"S Teppala","year":"2010","unstructured":"Teppala, S. & Shankar, A. Association between serum IGF-1 and diabetes among U.S. Adults. Diabetes Care. 33, 2257\u20132259 (2010).","journal-title":"Diabetes Care"},{"key":"22463_CR37","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.cell.2020.10.030","volume":"184","author":"Z Daniloski","year":"2021","unstructured":"Daniloski, Z. et al. Identification of required host factors for SARS-CoV-2 infection in human cells. Cell 184, 92\u2013105e16 (2021).","journal-title":"Cell"},{"key":"22463_CR38","doi-asserted-by":"publisher","first-page":"e00819","DOI":"10.1128\/AAC.00819-20","volume":"64","author":"S Jeon","year":"2020","unstructured":"Jeon, S. et al. Identification of antiviral drug candidates against SARS-CoV-2 from FDA-Approved drugs. Antimicrob. Agents Chemother. 64, e00819\u2013e00820 (2020).","journal-title":"Antimicrob. Agents Chemother."},{"key":"22463_CR39","doi-asserted-by":"publisher","unstructured":"Weston, S. et al. Broad Anti-coronavirus activity of food and drug Administration-Approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo. J. Virol. 94 https:\/\/doi.org\/10.1128\/jvi.01218-20 (2020).","DOI":"10.1128\/jvi.01218-20"},{"key":"22463_CR40","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41419-022-04961-z","volume":"13","author":"D Iaconis","year":"2022","unstructured":"Iaconis, D. et al. Characterization of raloxifene as a potential Pharmacological agent against SARS-CoV-2 and its variants. Cell. Death Dis. 13, 498 (2022).","journal-title":"Cell. Death Dis."},{"key":"22463_CR41","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/s41586-020-2286-9","volume":"583","author":"DE Gordon","year":"2020","unstructured":"Gordon, D. E. et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 583, 459\u2013468 (2020).","journal-title":"Nature"},{"key":"22463_CR42","first-page":"582310","volume":"11","author":"JM Vela","year":"2020","unstructured":"Vela, J. M. Repurposing Sigma-1 receptor ligands for COVID-19 therapy? Front. Pharmacol 11, 582310 (2020).","journal-title":"Pharmacol"},{"key":"22463_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/sj.bjp.0701079","volume":"121","author":"FF Moebius","year":"1997","unstructured":"Moebius, F. F., Reiter, R. J., Hanner, M. & Glossmann, H. High affinity of Sigma 1-binding sites for sterol isomerization inhibitors: evidence for a Pharmacological relationship with the yeast sterol C8-C7 isomerase. Br. J. Pharmacol. 121, 1\u20136 (1997).","journal-title":"Br. J. Pharmacol."},{"key":"22463_CR44","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/S0006-2952(99)00285-3","volume":"58","author":"B Kedjouar","year":"1999","unstructured":"Kedjouar, B. et al. Structural similitudes between cytotoxic antiestrogen-binding site (AEBS) ligands and cytotoxic Sigma receptor ligands. Evidence for a relationship between cytotoxicity and affinity for AEBS or Sigma-2 receptor but not for Sigma-1 receptor. Biochem. Pharmacol. 58, 1927\u20131939 (1999).","journal-title":"Biochem. Pharmacol."},{"key":"22463_CR45","doi-asserted-by":"crossref","unstructured":"Gastaminza, P., Whitten-Bauer, C. & Chisari, F. V. Unbiased probing of the entire hepatitis C virus life cycle identifies clinical compounds that target multiple aspects of the infection. Proc. Natl. Acad. Sci. 107, 291\u2013296 (2010).","DOI":"10.1073\/pnas.0912966107"},{"key":"22463_CR46","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.1128\/AAC.02619-14","volume":"58","author":"L Mingorance","year":"2014","unstructured":"Mingorance, L. et al. Selective Inhibition of hepatitis C virus infection by hydroxyzine and benztropine. Antimicrob. Agents Chemother. 58, 3451\u20133460 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"22463_CR47","doi-asserted-by":"publisher","first-page":"4885","DOI":"10.1128\/AAC.03036-14","volume":"58","author":"J Dyall","year":"2014","unstructured":"Dyall, J. et al. Repurposing of clinically developed drugs for treatment of middle East respiratory syndrome coronavirus infection. Antimicrob. Agents Chemother. 58, 4885\u20134893 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"22463_CR48","doi-asserted-by":"publisher","first-page":"190ra79","DOI":"10.1126\/scitranslmed.3005471","volume":"5","author":"LM Johansen","year":"2013","unstructured":"Johansen, L. M. et al. FDA-Approved selective Estrogen receptor modulators inhibit Ebola virus infection. Sci. Transl Med. 5, 190ra79 (2013).","journal-title":"Sci. Transl Med."},{"key":"22463_CR49","doi-asserted-by":"publisher","first-page":"4432","DOI":"10.1073\/pnas.96.8.4432","volume":"96","author":"N Altan","year":"1999","unstructured":"Altan, N., Chen, Y., Schindler, M. & Simon, S. M. Tamoxifen inhibits acidification in cells independent of the Estrogen receptor. Proc. Natl. Acad. Sci. 96, 4432\u20134437 (1999).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"22463_CR50","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/21548331.1993.11442764","volume":"28","author":"VC Jordan","year":"1993","unstructured":"Jordan, V. C. Targeted hormone therapy for breast cancer. Hosp. Pr. 28, 55\u201362 (1993).","journal-title":"Hosp. Pr"},{"key":"22463_CR51","unstructured":"Gallo, M. A. & Kaufman, D. Antagonistic and agonistic effects of tamoxifen: significance in human cancer. Semin Oncol 24, S1-71-S1-80 (1997)."},{"key":"22463_CR52","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41392-023-01488-3","volume":"8","author":"SS Barbieri","year":"2023","unstructured":"Barbieri, S. S. et al. Relevance of Spike\/Estrogen Receptor-\u03b1 interaction for endothelial-based coagulopathy induced by SARS-CoV-2. Signal. Transduct. Target. Ther. 8, 203 (2023).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"22463_CR53","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/nature02145","volume":"426","author":"W Li","year":"2003","unstructured":"Li, W. et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426, 450\u2013454 (2003).","journal-title":"Nature"},{"key":"22463_CR54","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.maturitas.2022.10.005","volume":"170","author":"Y Yoshida","year":"2023","unstructured":"Yoshida, Y. et al. Effect of menopausal hormone therapy on COVID-19 severe outcomes in women \u2013 A population-based study of the US National COVID cohort collaborative (N3C) data. Maturitas 170, 39\u201341 (2023).","journal-title":"Maturitas"},{"key":"22463_CR55","doi-asserted-by":"publisher","unstructured":"Nathan, M.R., Schmid, P. A Review of Fulvestrant in Breast Cancer. Oncol Ther. 5(1), 17-29. https:\/\/doi.org\/10.1007\/s40487-017-0046-2 (2017).","DOI":"10.1007\/s40487-017-0046-2"},{"key":"22463_CR56","doi-asserted-by":"publisher","first-page":"096368972199147","DOI":"10.1177\/0963689721991477","volume":"30","author":"S Bravaccini","year":"2021","unstructured":"Bravaccini, S. et al. Estrogen and androgen receptor inhibitors: unexpected allies in the fight against COVID-19. Cell. Transpl. 30, 0963689721991477 (2021).","journal-title":"Cell. Transpl."},{"key":"22463_CR57","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1200\/JCO.1991.9.2.286","volume":"9","author":"T Saphner","year":"1991","unstructured":"Saphner, T., Tormey, D. C. & Gray, R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J. Clin. Oncol. 9, 286\u2013294 (1991).","journal-title":"J. Clin. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22463-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22463-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22463-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:06:00Z","timestamp":1762351560000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22463-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["22463"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-22463-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"assertion":[{"value":"21 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GM has competing interests with Novartis, BMS, Roche, Pfizer, ARIAD, and MSD that are not related to the present study. All the other authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study has been approved by the local ethical committee (CEROM; protocol number IRST 100.51 ACT4COVID).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}}],"article-number":"38742"}}